<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996850</url>
  </required_header>
  <id_info>
    <org_study_id>18-001817</org_study_id>
    <secondary_id>NCI-2019-02711</secondary_id>
    <nct_id>NCT03996850</nct_id>
  </id_info>
  <brief_title>SPECT/CT for the Characterization of Renal Masses</brief_title>
  <official_title>SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well technetium Tc-99m sestamibi single-photon emission computed&#xD;
      tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with&#xD;
      kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a&#xD;
      less invasive way to check for kidney tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the impact of technetium Tc-99m sestamibi (MIBI) SPECT/CT on patient&#xD;
      management decisions.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the impact of MIBI SPECT/CT on patient management decisions for tumors 1.5-3.0&#xD;
      cm and 3.1-5.0 cm.&#xD;
&#xD;
      II. To assess the impact of MIBI SPECT/CT on decisional conflict score. III. To assess the&#xD;
      impact of MIBI SPECT/CT on physician management recommendation.&#xD;
&#xD;
      IV. To evaluate the sensitivity and specificity of MIBI SPECT/CT for the identification of an&#xD;
      oncocytic renal mass (oncocytoma, chromophobe, and hybrid oncocytic tumor) with respect to&#xD;
      tumor histology identified by renal mass biopsy or surgical resection.&#xD;
&#xD;
      V. To compare the specificity of MIBI SPECT/CT with conventional cross-sectional imaging in&#xD;
      predicting an oncocytic renal mass.&#xD;
&#xD;
      VI. To assess the correlation between MIBI SPECT/CT outcomes to final treatment decisions.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the mitochondria content in tumors that had positive MIBI SPECT/CT findings.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive technetium Tc-99m sestamibi intravenously (IV) then undergo SPECT/CT.&#xD;
&#xD;
      After completion of study, patients are followed up for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient management decision</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed with post-test, physician counseling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decision making based on tumor size</measure>
    <time_frame>6 months</time_frame>
    <description>Could be differentially impacted in two strata, tumors 1.5-3.0 cm and 3.1-5.0 cm.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Neoplasm</condition>
  <condition>Renal Mass</condition>
  <arm_group>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <description>Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Technetium Tc-99m Sestamibi</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <other_name>Cardiolite</other_name>
    <other_name>Miraluma</other_name>
    <other_name>Tc 99m Sestamibi</other_name>
    <other_name>Tc-99m MIBI</other_name>
    <other_name>Tc99m Sestamibi</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with new diagnosis of a renal tumor (within past 3 months)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Performance status Eastern Cooperative Oncology Group (ECOG) &lt; 2.&#xD;
&#xD;
          -  Life expectancy (&gt; 1 year).&#xD;
&#xD;
          -  New diagnosis of a renal tumor (within past 3 months).&#xD;
&#xD;
          -  Measurable, predominantly (&gt; 80%) solid renal neoplasm between 1.5-5.0 cm.&#xD;
&#xD;
          -  Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic&#xD;
             resonance imaging (MRI).&#xD;
&#xD;
          -  No definitive evidence of metastatic disease.&#xD;
&#xD;
          -  Does not require urgent surgical treatment.&#xD;
&#xD;
          -  Candidate for surgical, ablative, and surveillance approach.&#xD;
&#xD;
          -  Willingness to obtain more information to aid decision-making.&#xD;
&#xD;
          -  Understanding and willingness to provide consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of multiple solid renal tumors.&#xD;
&#xD;
          -  A prior needle biopsy of the mass resulting in histologic diagnosis.&#xD;
&#xD;
          -  A prior diagnosis of kidney cancer.&#xD;
&#xD;
          -  Presence of an active, untreated, non-renal malignancy.&#xD;
&#xD;
          -  History of bleeding diathesis or recent bleeding episode.&#xD;
&#xD;
          -  Prior surgery or radiation therapy to the kidney.&#xD;
&#xD;
          -  Unwillingness to fill out questionnaires.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Shuch</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Shuch</last_name>
      <phone>310-794-7700</phone>
      <email>BShuch@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Shuch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

